The Federal Trade Commission sued on Friday the three largest pharmaceutical intermediaries charged with negotiating drug prices on behalf of insurers, claiming they are illegally maximizing profits by steering patients to high-cost insulin products.

In January, a new Idaho law will take effect requiring reform of business practices by pharmacy middlemen — in search of tamping down prescription drug costs. The new law targets pharmacy benefit managers,

The federal government is suing some pharmacy benefit managers over a system of drug rebates that regulators say has made the price of insulin soar for patients